OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer

Launched by ·

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to monitor ovarian cancer in women whose usual blood test (called CA125) doesn’t show signs of the cancer coming back after their first treatment. The study uses a technology called exosome detection, which examines tiny particles released by cells, to see if it can better detect when the cancer might be returning. This could help doctors find a return of the cancer earlier and improve follow-up care.

Women between the ages of 65 and 74 who have ovarian cancer and whose CA125 test was negative at the start of their treatment may be eligible to join. Participants would be monitored using this new exosome-based test to see how well it works in spotting cancer recurrence. Since the trial hasn’t started recruiting yet, interested patients can talk with their doctor to learn more about whether this study might be right for them and what taking part would involve.

Gender

FEMALE

Eligibility criteria